Retatrutide vs Tirzepatide vs Semaglutide: mono, dual and triple

Research context (RUO): Retatrutide, tirzepatide and semaglutide are incretin receptor agonists studied in preclinical and clinical research for metabolism and body weight. All three are supplied by Peplife exclusively for in-vitro laboratory research (Research Use Only) — not for human or animal use.

Retatrutide vs tirzepatide vs semaglutide: mono, dual and triple

Retatrutide vs tirzepatide vs semaglutide is perhaps the most frequently asked question within research into incretin agonists. These three molecules represent three successive generations: a mono agonist (semaglutide), a dual agonist (tirzepatide) and a triple agonist (retatrutide). Each generation adds an extra hormone receptor to the mechanism of action, and in clinical studies this is accompanied by an increasingly larger reported effect on body weight. In this knowledge base pillar, researchers set out the mechanisms and study results of the three peptides side by side in a clear overview.

The three generations of incretin agonists in brief

Incretins are gut hormones that are released after a meal and control metabolism. The best known are GLP-1 (glucagon-like peptide-1) and GIP (glucose-dependent insulinotropic polypeptide). Glucagon is a related hormone that instead influences energy expenditure and liver metabolism. The three peptides differ precisely in how many of these receptors they activate at the same time:

• Semaglutide (mono, GLP-1): activates only the GLP-1 receptor. The first generation on which later research was built.
• Tirzepatide (dual, GIP/GLP-1): activates both the GIP and the GLP-1 receptor. In research, both signalling pathways reinforce each other.
• Retatrutide (triple, GIP/GLP-1/glucagon): activates GIP, GLP-1 and the glucagon receptor. The addition of glucagon agonism is linked in studies to higher energy expenditure.

Comparison table: mechanism and study results

The table below summarises the key differences as reported in the main registered studies. The weight-loss figures come from separate phase 2/3 trials with different design, duration and population — so a direct mutual comparison is indicative, not absolute.

Semaglutide: the mono-agonist (GLP-1)

Semaglutide was the reference point against which everything is measured. It activates only the GLP-1 receptor, a pathway associated in research with delayed gastric emptying and satiety signals in the brain. In the phase 3 study STEP 1 (Wilding et al., NEJM 2021), researchers reported an average body weight reduction of about 14.9% compared with placebo at a dose of 2.4 mg per week over 68 weeks. That result was for years the standard within GLP-1 research and formed the basis on which the later dual and triple molecules were designed.

Tirzepatide: the dual agonist (GIP/GLP-1)

Tirzepatide adds a second incretin pathway to the GLP-1 signal: GIP. In preclinical and clinical research the two pathways reinforce each other in insulin response and satiety. In the phase 3 trial SURMOUNT-1 (Jastreboff et al., NEJM 2022) researchers reported, in participants without diabetes over 72 weeks, an average weight loss rising to about 20.9% (treatment-regimen estimand) to 22.5% (treatment-adherence estimand; both analysis methods from the study) at the highest dose of 15 mg. In the head-to-head trial SURMOUNT-5 (NEJM 2025) tirzepatide was moreover set alongside semaglutide, with tirzepatide showing a larger effect on body weight in that study.

Retatrutide: the triple agonist (GIP/GLP-1/glucagon)

Retatrutide is the newest generation and the core of the search term retatrutide vs tirzepatide vs semaglutide. It combines the two incretin pathways of tirzepatide with a third: glucagon agonism. Where glucagon has traditionally been known for raising blood glucose, the controlled receptor activation is instead linked in this research to increased energy expenditure and effects on liver metabolism. In the phase 2 study (Jastreboff et al., NEJM 2023), researchers reported an average weight loss of up to about 24.2% at a dose of 12 mg over 48 weeks — the highest figure reported so far in a published trial in this class, and striking because the plateau did not appear to have been fully reached after 48 weeks. The phase 3 programmes around retatrutide are still ongoing at the time of writing.

What does “an extra receptor” mean in research practice?

The common thread is clear: in the reported studies, each added receptor is accompanied by a higher average weight loss — from around 15% (mono) to over 20% (dual) to about 24% (triple). Researchers do point out that the studies differ in duration (48 to 72 weeks), phase and participant population, so the figures are not one-to-one comparable. The side-effect profile — in particular gastrointestinal — and the long-term effect are also studied separately for each molecule. For laboratory research, it is mainly the mechanistic distinction between mono, dual and triple agonism that is relevant.

These peptides in laboratory research: handling & dissolving

Retatrutide, tirzepatide and semaglutide are supplied as lyophilised (freeze-dried) powder and reconstituted in a research setup with a suitable liquid. Which liquid is common for this in research and what researchers look for is described in the pillar dissolve peptide: which liquid and the accompanying reconstitution protocol. A broader placement of this class within the metabolic peptides can be found in comparing GLP-1 peptides.

Quality & purity

Every relevant batch of retatrutide, tirzepatide and semaglutide is independently HPLC-tested by an external laboratory; the certificate of analysis (CoA) is publicly verifiable per batch. For research into incretin agonists, a high, documented purity is essential: impurities or deviant peptide content can distort in-vitro results. Peplife therefore publishes the purity value and the accompanying CoA per batch, so that researchers can check their starting material before drawing up a protocol.

Frequently asked questions about retatrutide vs tirzepatide vs semaglutide

What is the difference between retatrutide, tirzepatide and semaglutide?
The difference lies in the number of activated receptors. Semaglutide is a mono agonist (GLP-1 only), tirzepatide a dual agonist (GIP + GLP-1) and retatrutide a triple agonist (GIP + GLP-1 + glucagon). In studies, each extra receptor is accompanied by a higher reported effect on body weight.

Which of the three showed the largest weight loss in research?
In the published trials, retatrutide reported the highest average: up to about 24.2% in the phase 2 study (12 mg, 48 weeks), compared with about 20.9–22.5% for tirzepatide (SURMOUNT-1) and about 14.9% for semaglutide (STEP 1). The studies differ in design, however, so the figures are indicative.

Why does retatrutide add glucagon?
Researchers study whether controlled glucagon receptor activation increases energy expenditure and influences liver metabolism, on top of the satiety and insulin effects of GIP and GLP-1. In the phase 2 data, this extra pathway was associated with a greater effect on weight.

Is retatrutide “better” than tirzepatide or semaglutide?
That cannot be stated firmly on the basis of separately conducted studies. Retatrutide shows the highest figures in phase 2, but the phase 3 programme is still running and the long-term and safety profile is still being studied. “Newer” or “stronger in one trial” does not automatically mean better for every research objective.

Are these peptides interchangeable in research?
No. They differ in receptor profile, potency and the dosages used in studies. For an in-vitro protocol they are treated as separate molecules, each with its own reference data.

May I use these peptides to lose weight?
No. Retatrutide, tirzepatide and semaglutide are supplied by Peplife exclusively for in-vitro laboratory research (Research Use Only). They are not intended for human or animal use and not approved for therapeutic application.

Read more & research at Peplife

• Research Retatrutide at Peplife
• Research Tirzepatide at Peplife
• Research Semaglutide at Peplife
• View all metabolism peptides
• Retatrutide research: the triple agonist mechanism
• Semaglutide vs tirzepatide compared
• comparing GLP-1 peptides
• Fat-loss peptides in research

Sources: Jastreboff et al., Triple–Hormone-Receptor Agonist Retatrutide for Obesity, NEJM 2023 · Jastreboff et al., Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1), NEJM 2022 · Wilding et al., Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1), NEJM 2021 · Aronne et al., Tirzepatide as Compared with Semaglutide (SURMOUNT-5), NEJM 2025

Research Use Only. All products are supplied exclusively for in vitro laboratory research. Not intended for diagnostic or therapeutic use in humans or animals, and not approved by the EMA or FDA.